# US 2023/0265127 A1 · Stabilized soluble pre-fusion rsv f polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265127 A1
- Document ID: US20230265127A1
- Status: Published application
- Kind: A1
- Application number: 17/821,694
- Filed: 2022-08-23
- Published: 2023-08-24
- Earliest claimed: 2013-04-25
- Assignees: Janssen Vaccines & Prevention B.V.
- Applicants: Janssen Vaccines & Prevention B.V.
- Inventors: Johannes Petrus Maria LANGEDIJK; Anders Krarup
- Web page: https://patentgrep.com/patent/US20230265127A1

## CPC

- C07K 14/005: from viruses
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/12: Viral antigens
- A61K 39/155: Paramyxoviridae, e.g. parainfluenza virus
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/14: for RNA viruses
- C07K 14/135: Respiratory syncytial virus
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/70: containing domain for protein-protein interaction
- C07K 2319/73: containing coiled-coiled motif (leucine zippers)
- C12N 2760/18522: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/18534: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described are stable pre-fusion respiratory syncitial virus (RSV) F polypeptides, immunogenic compositions comprising the polypeptides and uses thereof for the prevention and/or treatment of RSV infection.

## Claims

### Claim at position 1

-27. (canceled)

### Claim 28

A recombinant pre-fusion respiratory syncytial virus (RSV) Fusion (F) polypeptide comprising:
a mutation of the amino acid residue N/T at position 67 into I,
a mutation of the amino acid residue S at position 215 into P, and
a mutation of the amino acid residue D at position 486 into N,
wherein the amino acid positions are given in reference to the sequence of RSV F protein from the A2 strain (SEQ ID NO: 1).

### Claim 29 (depends on 28)

The recombinant pre-fusion RSV F polypeptide according to claim 28, wherein the polypeptide comprises a truncated F1 domain and an F2 domain.

### Claim 30 (depends on 29)

The recombinant pre-fusion RSV F polypeptide according to claim 29, wherein the polypeptide comprises a heterologous trimerization domain linked to the truncated F1 domain, wherein the heterologous trimerization domain comprises the amino acid sequence
(SEQ ID NO: 4)
GYIPEAPRDGQAYVRKDGEWVLLSTFL.

### Claim 31 (depends on 30)

The recombinant pre-fusion RSV F polypeptide according to claim 30, wherein the trimerization domain is linked to amino acid 513 of the truncated F1 domain by a linker sequence.

### Claim 32 (depends on 31)

The recombinant pre-fusion RSV F polypeptide according to claim 31, wherein the linker comprises SEQ ID NO: 5.

### Claim 33 (depends on 28)

The recombinant pre-fusion RSV F polypeptide according to claim 28, wherein the F1 domain and/or the F2 domain are from an RSV A strain.

### Claim 34 (depends on 28)

The recombinant pre-fusion RSV F polypeptide according to claim 28, wherein the F1 domain and/or the F2 domain are from an RSV B strain.

### Claim 35 (depends on 28)

A composition comprising the recombinant pre-fusion RSV F polypeptide according to claim 28 and a pharmaceutically acceptable carrier or excipient.

### Claim 36 (depends on 30)

A composition comprising the recombinant pre-fusion RSV F polypeptide according to claim 30 and a pharmaceutically acceptable carrier or excipient.

### Claim 37 (depends on 28)

A nucleic acid molecule encoding the pre-fusion RSV F mutant polypeptide of claim 28.

### Claim 38 (depends on 28)

A vector comprising a nucleic acid molecule encoding a pre-fusion RSV F polypeptide according to claim 28, wherein the vector is an adenoviral vector.

### Claim 39 (depends on 38)

The vector according to claim 38, wherein the adenoviral vector is an adenovirus serotype 26 (Ad26) vector.

### Claim 40 (depends on 38)

A composition comprising the vector according to claim 38 and a pharmaceutically acceptable carrier or excipient.

### Claim 41 (depends on 28)

A composition comprising a recombinant pre-fusion RSV F polypeptide according to claim 28 and a vector comprising a nucleic acid molecule encoding the same.

### Claim 42 (depends on 30)

A composition comprising a recombinant pre-fusion RSV F polypeptide according to claim 30 and an adenoviral vector comprising a nucleic acid molecule encoding a pre-fusion RSV F polypeptide comprising: a mutation of the amino acid residue N/T at position 67 into I, a mutation of the amino acid residue S at position 215 into P, and a mutation of the amino acid residue D at position 486 into N, wherein the amino acid positions are given in reference to the sequence of RSV F protein from the A2 strain (SEQ ID NO: 1).

### Claim 43 (depends on 30)

A method of inducing an immune response against RSV F protein in a subject, the method comprising administering to the subject a recombinant pre-fusion RSV F polypeptide according to claim 30 and an adenoviral vector comprising a nucleic acid molecule encoding a pre-fusion RSV F polypeptide comprising: a mutation of the amino acid residue N/T at position 67 into I, a mutation of the amino acid residue S at position 215 into P, and a mutation of the amino acid residue D at position 486 into N, wherein the amino acid positions are given in reference to the sequence of RSV F protein from the A2 strain (SEQ ID NO: 1).

### Claim 44 (depends on 43)

The method according to claim 43, wherein the adenoviral vector is an adenovirus serotype 26 (Ad26) vector.

### Claim 44 (depends on 45)

The method according to claim 45, wherein the adenoviral vector is an adenovirus serotype 26 (Ad26) vector.

### Claim 45 (depends on 30)

A method of prophylaxing and/or treating RSV infection in a subject, the method comprising administering to the subject the recombinant pre-fusion RSV F polypeptide according to claim 30 and an adenoviral vector comprising a nucleic acid molecule encoding a pre-fusion RSV F polypeptide comprising: a mutation of the amino acid residue N/T at position 67 into I, a mutation of the amino acid residue S at position 215 into P, and a mutation of the amino acid residue D at position 486 into N, wherein the amino acid positions are given in reference to the sequence of RSV F protein from the A2 strain (SEQ ID NO: 1), to prophylax against and/or treat the subject for RSV infection.
